For the quarter ended December 31, 2024, Orchid received $185.0 million in scheduled and unscheduled principal repayments and prepayments, which equated to a 3-month constant prepayment rate (“CPR”) ...
Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Spero Therapeutics (SPRO – Research Report), retaining the price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback